Aric Madayag joined the Rare Disease Translational Center (RDTC) in February 2024, focusing on neurodegenerative and neurodevelopmental disorders, with additional contributions to lysosomal storage and metabolic disease research.
He earned a B.S. in Physics from Georgia Tech before pursuing a Ph.D. in Neurobiology at Marquette University, where he studied cortico-accumbal pathways in cocaine-seeking and relapse behavior. Aric completed postdoctoral fellowships at the University of North Carolina, Chapel Hill—researching astrocytes and prefrontal neurocircuitry in adolescent binge ethanol exposure—and at Marquette, where he used patch-clamp electrophysiology to study opioid effects on nucleus accumbens neurons.
Following his postdoctoral work, Aric led lab and research operations at NeuroCycle Therapeutics, identifying novel benzodiazepine therapeutics for seizure disorders.
He joined JAX in winter 2021, conducting preclinical IND-enabling research in ALS and Alzheimer’s disease models for pharmaceutical and biotech partners.